
Gregory S. Emch
Examiner (ID: 8394, Phone: (571)272-8149 , Office: P/1649 )
| Most Active Art Unit | 1649 |
| Art Unit(s) | 1678, 1699, 1649 |
| Total Applications | 893 |
| Issued Applications | 386 |
| Pending Applications | 80 |
| Abandoned Applications | 436 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16962924
[patent_doc_number] => 20210214423
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => MUTATIONS THAT DRIVE VH4 ANTIBODY AUTOREACTIVITY
[patent_app_type] => utility
[patent_app_number] => 16/074166
[patent_app_country] => US
[patent_app_date] => 2017-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16074166
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/074166 | Mutations that drive VH4 antibody autoreactivity | Jan 30, 2017 | Issued |
Array
(
[id] => 11823165
[patent_doc_number] => 20170212102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-07-27
[patent_title] => 'BIOMARKERS'
[patent_app_type] => utility
[patent_app_number] => 15/416789
[patent_app_country] => US
[patent_app_date] => 2017-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 11772
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15416789
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/416789 | Quantifying biomarkers for diagnosing and treating schizophrenia, bipolar disorder or major depression | Jan 25, 2017 | Issued |
Array
(
[id] => 11836339
[patent_doc_number] => 20170218058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-08-03
[patent_title] => 'ANTI-APOE4 ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/414955
[patent_app_country] => US
[patent_app_date] => 2017-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 57673
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414955
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/414955 | ANTI-APOE4 ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | Jan 24, 2017 | Abandoned |
Array
(
[id] => 11649611
[patent_doc_number] => 20170145511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-25
[patent_title] => 'METHODS AND ASSAYS RELATING TO HUNTINGTONS DISEASE AND PARKINSON\'S DISEASE'
[patent_app_type] => utility
[patent_app_number] => 15/411329
[patent_app_country] => US
[patent_app_date] => 2017-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 35
[patent_no_of_words] => 79826
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411329
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/411329 | Methods and assays relating to Huntingtons disease and Parkinson's disease | Jan 19, 2017 | Issued |
Array
(
[id] => 11969887
[patent_doc_number] => 20170274041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-28
[patent_title] => 'Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury'
[patent_app_type] => utility
[patent_app_number] => 15/400664
[patent_app_country] => US
[patent_app_date] => 2017-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 45614
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400664
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/400664 | Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury | Jan 5, 2017 | Abandoned |
Array
(
[id] => 17497840
[patent_doc_number] => 11286533
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-29
[patent_title] => Biomarkers of chronic lymphocytic leukemia and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/063784
[patent_app_country] => US
[patent_app_date] => 2016-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 13851
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 194
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16063784
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/063784 | Biomarkers of chronic lymphocytic leukemia and use thereof | Dec 18, 2016 | Issued |
Array
(
[id] => 17103122
[patent_doc_number] => 11123311
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-21
[patent_title] => Methods of treating mental disorders
[patent_app_type] => utility
[patent_app_number] => 16/065907
[patent_app_country] => US
[patent_app_date] => 2016-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 26104
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065907
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/065907 | Methods of treating mental disorders | Dec 14, 2016 | Issued |
Array
(
[id] => 14497949
[patent_doc_number] => 20190192629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-27
[patent_title] => Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases
[patent_app_type] => utility
[patent_app_number] => 15/777222
[patent_app_country] => US
[patent_app_date] => 2016-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777222
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/777222 | Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases | Nov 17, 2016 | Abandoned |
Array
(
[id] => 13944711
[patent_doc_number] => 10208111
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-19
[patent_title] => Alpha-synuclein antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 15/355543
[patent_app_country] => US
[patent_app_date] => 2016-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 63
[patent_no_of_words] => 13224
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355543
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/355543 | Alpha-synuclein antibodies and uses thereof | Nov 17, 2016 | Issued |
Array
(
[id] => 11492632
[patent_doc_number] => 20170066817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-09
[patent_title] => 'MONOCLONAL ANTIBODY AGAINST HUMAN PRPC AND USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/351418
[patent_app_country] => US
[patent_app_date] => 2016-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 6885
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15351418
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/351418 | Monoclonal antibody against human PrPc and use thereof | Nov 13, 2016 | Issued |
Array
(
[id] => 11472801
[patent_doc_number] => 20170059585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-03-02
[patent_title] => 'In vitro detection of prions in blood'
[patent_app_type] => utility
[patent_app_number] => 15/330832
[patent_app_country] => US
[patent_app_date] => 2016-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 11590
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15330832
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/330832 | In vitro detection of prions in blood | Nov 6, 2016 | Issued |
Array
(
[id] => 11441958
[patent_doc_number] => 20170042980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-02-16
[patent_title] => 'Degradation of Beta-Amyloid Proteins With Keratinase'
[patent_app_type] => utility
[patent_app_number] => 15/339093
[patent_app_country] => US
[patent_app_date] => 2016-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 578
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15339093
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/339093 | Degradation of Beta-Amyloid Proteins With Keratinase | Oct 30, 2016 | Abandoned |
Array
(
[id] => 11604085
[patent_doc_number] => 20170121385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-04
[patent_title] => 'METHODS OF TREATING NEURODEGENERATIVE CONDITIONS'
[patent_app_type] => utility
[patent_app_number] => 15/338159
[patent_app_country] => US
[patent_app_date] => 2016-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72492
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15338159
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/338159 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | Oct 27, 2016 | Abandoned |
Array
(
[id] => 17268513
[patent_doc_number] => 11193933
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-07
[patent_title] => Measuring GAPDH protein for diagnosis and treatment of alzheimer's disease
[patent_app_type] => utility
[patent_app_number] => 15/335036
[patent_app_country] => US
[patent_app_date] => 2016-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 3703
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15335036
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/335036 | Measuring GAPDH protein for diagnosis and treatment of alzheimer's disease | Oct 25, 2016 | Issued |
Array
(
[id] => 12786412
[patent_doc_number] => 20180153973
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-07
[patent_title] => DNA VACCINE AGAINST AMYLOID-BETA AND TAU
[patent_app_type] => utility
[patent_app_number] => 15/578123
[patent_app_country] => US
[patent_app_date] => 2016-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15578123
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/578123 | DNA vaccine against amyloid-b and tau | Oct 19, 2016 | Issued |
Array
(
[id] => 11542650
[patent_doc_number] => 20170096476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-04-06
[patent_title] => 'METHODS AND COMPOSITIONS RELATED TO AMYLOID-BETA-42 OLIGOMERS'
[patent_app_type] => utility
[patent_app_number] => 15/283779
[patent_app_country] => US
[patent_app_date] => 2016-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 10162
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15283779
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/283779 | METHODS AND COMPOSITIONS RELATED TO AMYLOID-BETA-42 OLIGOMERS | Oct 2, 2016 | Abandoned |
Array
(
[id] => 12368097
[patent_doc_number] => 09957568
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-05-01
[patent_title] => Administration of FGF9 for treatment and prevention of major depression
[patent_app_type] => utility
[patent_app_number] => 15/270193
[patent_app_country] => US
[patent_app_date] => 2016-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 67
[patent_figures_cnt] => 66
[patent_no_of_words] => 52606
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15270193
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/270193 | Administration of FGF9 for treatment and prevention of major depression | Sep 19, 2016 | Issued |
Array
(
[id] => 15975497
[patent_doc_number] => 10668049
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-06-02
[patent_title] => Methods of treating cognitive decline with transforming growth factor beta inhibitors
[patent_app_type] => utility
[patent_app_number] => 15/258862
[patent_app_country] => US
[patent_app_date] => 2016-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 65
[patent_no_of_words] => 26336
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15258862
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/258862 | Methods of treating cognitive decline with transforming growth factor beta inhibitors | Sep 6, 2016 | Issued |
Array
(
[id] => 11618344
[patent_doc_number] => 20170128531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-05-11
[patent_title] => 'TREATING NEURODEGENERATIVE DISEASES WITH PROGRANULIN'
[patent_app_type] => utility
[patent_app_number] => 15/255948
[patent_app_country] => US
[patent_app_date] => 2016-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 20059
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15255948
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/255948 | TREATING NEURODEGENERATIVE DISEASES WITH PROGRANULIN | Sep 1, 2016 | Abandoned |
Array
(
[id] => 11730575
[patent_doc_number] => 20170192017
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-07-06
[patent_title] => 'Methods For Detecting Phosphorylated Alpha-Synuclein'
[patent_app_type] => utility
[patent_app_number] => 15/247598
[patent_app_country] => US
[patent_app_date] => 2016-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 10879
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 23
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15247598
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/247598 | Methods for detecting phosphorylated alpha-synuclein | Aug 24, 2016 | Issued |